Johnson & Johnson, Sanofi Top the 2017 Good Pharma Scorecard

Dec 05, 2017

The second publication of Bioethics International's Good Pharma Scorecard, an annual index ranking large pharmaceutical companies and new drugs on their clinical trial transparency, was published in BMJ Open. 

Johnson & Johnson and Sanofi, two of eleven ranked companies achieved the highest overall clinical trial transparency scores, both scoring 100%. AbbVie, Celgene, Merck, and Astra Zeneca all scored at or above the industry median.  

“We created the GPS to help advance trustworthiness and ethics in the pharmaceutical sector, by setting clear ethics standards and benchmarking the performance of companies against those standards every year,” said Jennifer E. Miller, Ph.D., founder of Bioethics International and lead author on the paper. “This year’s Scorecard shows clear corporate leaders in clinical trial transparency and industry improvement on several metrics. We hope this improvement continues year after year, because clinical trial transparency is critical for advancing innovation, respect for trial participants, and patient health.”

The 2017 GPS ranking evaluates clinical trial registration, results reporting, clinical study report synopsis sharing, and journal article publication rates for new drugs approved by the Food and Drug Administration  in 2014 that were sponsored by large drug companies. 

lorem ipsum